Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy

British Journal of Dermatology

Volumn 163, Issue 4, 2010, Pages 832-837

  Arena, C ^a,b   Morin, A S ^c   Blanchon, T ^a,b   Hanslik, T ^a,b,d   Cabane, J ^b,e   Dupuy, A ^f,g   Fardet, L ^a,b,f  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL JEAN VERDIER   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

adherence; adverse events; compliance; glucocorticoids

Indexed keywords

GLUCOCORTICOID; PREDNISOLONE; PREDNISONE;

ADULT; ANAPHYLACTOID PURPURA; ARTICLE; AVASCULAR NECROSIS; BUFFALO NECK; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DIETARY INTAKE; EPIGASTRIC PAIN; FEMALE; GIANT CELL ARTERITIS; HAND TREMOR; HUMAN; HYPERTENSION; INSOMNIA; LOCALIZED SCLERODERMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; MOON FACE; MORPHOLOGY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYOSITIS; NAUSEA AND VOMITING; PATIENT COMPLIANCE; POLYARTERITIS NODOSA; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BRUISING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; WEGENER GRANULOMATOSIS; WEIGHT GAIN; WOUND HEALING;

ADULT; AGED; CONNECTIVE TISSUE DISEASES; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; VASCULITIS;

EID: 77957066552     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09877.x     Document Type: Article

References (33)

1. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva : World Health Organization, 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence-full-report.pdf (last accessed 4 June 2010).
2. Morant SV, McMahon AD, Cleland JG et al. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004 57 : 188 198.
3. Butler JA, Roderick P, Mullee M et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004 77 : 769 789.
4. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000 133 : 21 30.
5. Duran S, Savès M, Spire B et al. APROCO Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001 15 : 2441 2444.
6. Braithwaite RS, Kozal MJ, Chang CC et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007 21 : 1579 1589.
7. Ickovics JR, Cameron A, Zackin R et al. Adult AIDS Clinical Trials Group 370 Protocol Team. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther 2002 7 : 185 193.
8. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995 310 : 1433 1438.
9. Fardet L, Flahault A, Kettaneh A et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007 157 : 142 148.
10. Cullen G, Kelly E, Murray FE. Patients' knowledge of adverse reactions to current medications. Br J Clin Pharmacol 2006 62 : 232 236.
11. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007 30 : 861 881.
12. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999 14 : 1 24.
13. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986 24 : 67 74.
14. Sewitch MJ, Abrahamowicz M, Barkun A et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003 98 : 1535 1544.
15. Prado JC Jr., Kupek E, Mion D Jr. Validity of four indirect methods to measure adherence in primary care hypertensives. J Hum Hypertens 2007 21 : 579 584.
16. Haynes RB, Taylor DW, Sackett DL et al. Can simple clinical measures detect patient noncompliance? Hypertension 1980 2 : 757 764.
17. Val Jimenez A, Amoros Ballestero G, Martinez Visa P et al. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test [in Spanish]. Aten Primaria 1992 10 : 767 770.
18. Anastasio GD, Little JM Jr., Robinson MD et al. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. Pharmacotherapy 1994 14 : 229 234.
19. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther 2008 10 : R53.
20. Thiéfin G, Schaeverbeke T, Barthélémy P et al. Upper gastrointestinal symptoms in patients treated with nonsteroidal anti-inflammatory drugs: prevalence and impact - the COMPLAINS study. Eur J Gastroenterol Hepatol 2010 22 : 81 7.
21. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994 236 : 599 601.
22. Messer J, Reitman D, Sacks HS et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983 309 : 21 4.
23. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002 136 : 1 12.
24. Ammassari A, Antinori A, Cozzi-Lepri A et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002 31 : S140 4.
25. Capeau J, Magré J, Lascols O et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans 2005 33 : 1073 1077.
26. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 353 : 2093 2099.
27. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001 32 : 130 139.
28. Fardet L, Cabane J, Kettaneh A et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) 2007 46 : 1102 1106.
29. Fardet L, Cabane J, Lebbé C et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol 2007 57 : 604 609.
30. Duran S, Spire B, Raffi F et al. APROCO Cohort Study Group. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001 2 : 38 45.
31. Matsui D, Hermann C, Klein J et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 1994 34 : 944 949.
32. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 1983 5 : 319 332.
33. Hoes JN, Jacobs JW, Boers M et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007 66 : 1560 1567.